{"id":"lcp-tacrolimus-qd-mmf-bid","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Neurotoxicity (tremor, headache)"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Leukopenia"}]},"_chembl":{"chemblId":"CHEMBL3989887","moleculeType":"Small molecule","molecularWeight":"822.05"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus is a calcineurin inhibitor that blocks T-cell activation by inhibiting IL-2 production, while MMF is an inosine monophosphate dehydrogenase inhibitor that selectively suppresses lymphocyte proliferation. The LCP (Lipid Conjugate Platform) formulation provides once-daily dosing of tacrolimus, improving adherence in immunosuppressive regimens. Together, these agents provide complementary immunosuppression for transplant rejection prevention.","oneSentence":"LCP-tacrolimus is a prolonged-release formulation of tacrolimus combined with mycophenolate mofetil (MMF) to suppress T-cell mediated immune responses and prevent organ rejection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:51:40.326Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in transplant recipients (kidney, heart, liver transplantation)"}]},"trialDetails":[{"nctId":"NCT06354179","phase":"PHASE4","title":"Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)","status":"RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2025-04-15","conditions":"Liver Transplantation, Immunosuppression","enrollment":162},{"nctId":"NCT01187953","phase":"PHASE3","title":"Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2010-09","conditions":"Renal Failure","enrollment":543}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"LCP-tacrolimus QD + MMF BID","genericName":"LCP-tacrolimus QD + MMF BID","companyName":"University Hospital, Limoges","companyId":"university-hospital-limoges","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LCP-tacrolimus is a prolonged-release formulation of tacrolimus combined with mycophenolate mofetil (MMF) to suppress T-cell mediated immune responses and prevent organ rejection. Used for Prevention of organ rejection in transplant recipients (kidney, heart, liver transplantation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}